IRVINE, Calif., Aug. 22, 2011 /PRNewswire/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), the global leader in medical aesthetic
devices, kicks off the rock of all ages tour with the introduction
of The I Wanna Be Sublated, Road to Rejuvenation World Tour – a
consumer awareness campaign developed to inspire and revolutionize
the landscape of anti-aging with a novel, non-surgical, treatment
category in facial rejuvenation - Sublative®. "Sublative
rejuvenation is the byproduct of countless product development
discussions with the brightest minds in Dermatology and Plastic
Surgery," said Louis P. Scafuri,
Chief Executive Officer of Syneron. "The driving topic
remains centered on what we can do to meet the needs of our
customers' patient base and inspire exciting and innovative
advancements in our field. Physicians and patients have come to
agree that Sublative is the answer to both points."
At first glance the Sublative treatment is already sparking new
light for future aesthetic applications as the world's first
treatment powered solely by fractionated, bi-polar radio-frequency.
"Syneron's expertise as an innovator of radio-frequency
technology spans over a decade," said James
Bartholomeusz, Global Vice President of Product Development
of Syneron. "Our Sublative technology is the latest evolution
to captivate the facial rejuvenation world with a novel treatment
that transcends through all skin types and age groups. Its
versatility amplified with effectiveness positions Sublative as the
ideal treatment for the modern-day patient on the go."
Safe and effective for all skin types and age groups, experts
will agree that Sublative stands alone in energy-based facial
cosmetic applications due to its unique energy delivery model.
"To achieve the best possible results when addressing skin
imperfections it is essential that the energy reaches below the
skin without overheating the top layer of the skin," said Dr.
Doris Day, M.D., board-certified
Dermatologist at My Clear Skin Day Dermatology and Aesthetics in
Manhattan, New York.
"Sublative finally provides me with a proven solution to this
long-known theory and opens up an option for a much wider patient
base in my practice." "For my patients that are looking to
rejuvenate their overall complexion without significant downtime,
Sublative has been a nice addition to our practice," said
Jason Diamond, M.D. board-certified
Facial Plastic and Reconstructive Surgeon at The Diamond Face
Institute in Beverly Hills,
California and featured star on the hit show Dr.
90210.
The coast-to-coast tour is scheduled to reach major cities like
Los Angeles and New York in addition to other metropolitan
cities such as Phoenix,
Denver, Miami, Tampa,
San Francisco, San Diego and Chicago. The tour will consist of a
variety of different educational events such as open houses,
gifting suites and press events. Exclusive Backstage Passes
that provide direct access to some of the world-renowned
Dermatologists and Plastic Surgeons for a first-hand experience to
be Sublated are available for interested media personnel.
For more information about obtaining the Exclusive I Wanna Be
Sublated Backstage Pass contact pr@syneron.com or follow our tour
updates by liking us on Facebook (Sublative) or following us on
Twitter (@sublative). To locate a local treatment provider
also visit www.sublativeskin.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology,
real science and real results – is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables physicians
to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. The Company's aspiration and commitment to innovation
expands Syneron's offering beyond medical devices into the largest
in-demand applications in beauty - skin lightening. Founded in
2000, the corporate, R&D, and manufacturing headquarters for
Syneron Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts:
Syneron – Public Relations
pr@syneron.com
David Sands
Hollywood Branded Inc.
323-271-4942
david@hollywoodbranded.com
SOURCE Syneron Medical Ltd.